With the development of the Phase I Program at Yale Cancer Center there are currently 45 Phase I trials open and that number is growing. Phase I trials allow clinicians to look for new causes for drug effectiveness or drug resistance. These early trials bring in additional resources for the work that needs to be done by our researchers.
Among the most exciting trials now underway are five using “checkpoint inhibitor” immunotherapies that activate the immune system and shrink tumors. The targets are melanoma, kidney cancer, lung cancer, and others. These trials have built Yale Cancer Center’s reputation as an innovator in immune-based therapies.
Under the leadership of Joseph Paul Eder, MD, Director of Experimental Therapeutics and Clinical Program Leader of the Phase I Research Group, and Patricia LoRusso, DO, Disease Aligned Research Team Leader (DART), Yale Cancer Center has been established as a place that can get additional funding to help basic scientists explore new areas, and the NIH is more likely to fund work that intersects with clinical medicine. The goal of the program is not just to accrue patients to certain trials, but to also make progress in the scientific understanding of the disease and treatment.